The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer

Research output: Contribution to journalArticle

Abstract

Importance of the field: Prostate cancer is the mostly commonly diagnosed non-skin cancer in males. The culmination of the last 70 years of clinical drug development has documented that androgen ablation plus taxane-based systemic chemotherapy enhances survival, but is not curative, in metastatic prostate cancer. To effect curative therapy, additional drugs must be developed that enhance the response when combined with androgen ablation/taxane therapy. Areas covered in this review: The history of the discovery and development of tasquinimod as a second-generation oral quinoline-3-carboxamide analogue for prostate cancer will be presented. What the reader will gain: The mechanism for such anticancer efficacy is via tasquinimod's ability to inhibit the 'angiogenic switch' within cancer sites required for their continuous lethal growth. Take home message: Tasquinimod is a novel inhibitor of tumor angiogenesis that enhances the therapeutic anticancer response when combined with other standard-of-care modalities (radiation, androgen ablation, and/or taxane-based chemotherapies) in experimental animal models, but does not inhibit normal wound healing. It has successfully completed clinical Phase II testing in humans and will shortly enter registration Phase III evaluation for the treatment of metastatic prostate cancer.

Original languageEnglish (US)
Pages (from-to)1235-1243
Number of pages9
JournalExpert Opinion on Investigational Drugs
Volume19
Issue number10
DOIs
StatePublished - Oct 2010

Fingerprint

Prostatic Neoplasms
Androgens
Drug Therapy
Pharmaceutical Preparations
Neoplasms
Angiogenesis Inhibitors
Therapeutics
Standard of Care
Wound Healing
Animal Models
History
Radiation
Survival
quinoline-3-carboxamide
tasquinimod
Growth
taxane

Keywords

  • antiangiogenic agent
  • prostate cancer
  • quinoline-3-carboxamide
  • tasquinimod

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{f2a04d7456374817a8fc4d2ec1dd0ba7,
title = "The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer",
abstract = "Importance of the field: Prostate cancer is the mostly commonly diagnosed non-skin cancer in males. The culmination of the last 70 years of clinical drug development has documented that androgen ablation plus taxane-based systemic chemotherapy enhances survival, but is not curative, in metastatic prostate cancer. To effect curative therapy, additional drugs must be developed that enhance the response when combined with androgen ablation/taxane therapy. Areas covered in this review: The history of the discovery and development of tasquinimod as a second-generation oral quinoline-3-carboxamide analogue for prostate cancer will be presented. What the reader will gain: The mechanism for such anticancer efficacy is via tasquinimod's ability to inhibit the 'angiogenic switch' within cancer sites required for their continuous lethal growth. Take home message: Tasquinimod is a novel inhibitor of tumor angiogenesis that enhances the therapeutic anticancer response when combined with other standard-of-care modalities (radiation, androgen ablation, and/or taxane-based chemotherapies) in experimental animal models, but does not inhibit normal wound healing. It has successfully completed clinical Phase II testing in humans and will shortly enter registration Phase III evaluation for the treatment of metastatic prostate cancer.",
keywords = "antiangiogenic agent, prostate cancer, quinoline-3-carboxamide, tasquinimod",
author = "Isaacs, {John Tod}",
year = "2010",
month = "10",
doi = "10.1517/13543784.2010.514262",
language = "English (US)",
volume = "19",
pages = "1235--1243",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "10",

}

TY - JOUR

T1 - The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer

AU - Isaacs, John Tod

PY - 2010/10

Y1 - 2010/10

N2 - Importance of the field: Prostate cancer is the mostly commonly diagnosed non-skin cancer in males. The culmination of the last 70 years of clinical drug development has documented that androgen ablation plus taxane-based systemic chemotherapy enhances survival, but is not curative, in metastatic prostate cancer. To effect curative therapy, additional drugs must be developed that enhance the response when combined with androgen ablation/taxane therapy. Areas covered in this review: The history of the discovery and development of tasquinimod as a second-generation oral quinoline-3-carboxamide analogue for prostate cancer will be presented. What the reader will gain: The mechanism for such anticancer efficacy is via tasquinimod's ability to inhibit the 'angiogenic switch' within cancer sites required for their continuous lethal growth. Take home message: Tasquinimod is a novel inhibitor of tumor angiogenesis that enhances the therapeutic anticancer response when combined with other standard-of-care modalities (radiation, androgen ablation, and/or taxane-based chemotherapies) in experimental animal models, but does not inhibit normal wound healing. It has successfully completed clinical Phase II testing in humans and will shortly enter registration Phase III evaluation for the treatment of metastatic prostate cancer.

AB - Importance of the field: Prostate cancer is the mostly commonly diagnosed non-skin cancer in males. The culmination of the last 70 years of clinical drug development has documented that androgen ablation plus taxane-based systemic chemotherapy enhances survival, but is not curative, in metastatic prostate cancer. To effect curative therapy, additional drugs must be developed that enhance the response when combined with androgen ablation/taxane therapy. Areas covered in this review: The history of the discovery and development of tasquinimod as a second-generation oral quinoline-3-carboxamide analogue for prostate cancer will be presented. What the reader will gain: The mechanism for such anticancer efficacy is via tasquinimod's ability to inhibit the 'angiogenic switch' within cancer sites required for their continuous lethal growth. Take home message: Tasquinimod is a novel inhibitor of tumor angiogenesis that enhances the therapeutic anticancer response when combined with other standard-of-care modalities (radiation, androgen ablation, and/or taxane-based chemotherapies) in experimental animal models, but does not inhibit normal wound healing. It has successfully completed clinical Phase II testing in humans and will shortly enter registration Phase III evaluation for the treatment of metastatic prostate cancer.

KW - antiangiogenic agent

KW - prostate cancer

KW - quinoline-3-carboxamide

KW - tasquinimod

UR - http://www.scopus.com/inward/record.url?scp=77956562643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956562643&partnerID=8YFLogxK

U2 - 10.1517/13543784.2010.514262

DO - 10.1517/13543784.2010.514262

M3 - Article

C2 - 20836618

AN - SCOPUS:77956562643

VL - 19

SP - 1235

EP - 1243

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 10

ER -